In 2025, the retail segment of the Russian pharmaceutical market reached RUB 1.89 trillion at retail prices, including VAT. Compared with 2024, the market’s value increased by 15.8%. Over the year, residents of Russia (including the new regions) purchased 4.93 billion packages of medicines, which is 1.8% more than in 2024. According to the “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)” database of the analytical company RNC Pharma, products from more than 830 different corporations were present on the Russian retail market in 2025.

The top ten companies accounted for 28% of the total market value. Notably, this share has been gradually declining over time: in 2022, the TOP-10 generated around 30% of total retail sales. At the same time, significant changes occurred in the rankings in 2025, including a change of market leader.

The German concern Bayer, which had held the leading position for many years largely due to its blockbuster product Xarelto, dropped to second place, уступив leadership to the Nizhpharm Group. It should be noted that the new leader outperformed Bayer by only a few thousandths of a percentage point. The primary reason for this shift was the expiration of patent protection for Bayer’s key product. In 2025, the share of Xarelto in Bayer’s portfolio declined from 28.5% in 2024 to 21.5% in value terms. Overall, Bayer marketed 63 brands on the Russian market last year.

Nizhpharm, which had consistently ranked second since 2023, demonstrated stable value growth and ultimately moved to the top position. For a long time, the company’s leading brand has been Edarbi, an antihypertensive drug. Compared with 2024, sales of Edarbi increased by 26%, significantly contributing to the group’s overall performance.

No changes occurred in positions three through five of the corporate ranking. These places continue to be occupied by international companies Servier, Abbott, and Sanofi, all of which showed strong value growth compared with 2024. Teva moved down to seventh place, giving way to KRKA, which ranked sixth at the end of 2025. Both companies demonstrated double-digit growth rates in value terms, with increases of 12.6% and 15.8%, respectively. For KRKA, growth in 2025 was driven primarily by hypolipidemic and anti-ulcer medications.

Among domestic manufacturers, Ozon Pharmaceuticals stood out in particular: over the year, sales of its products increased by 38% in value terms and by 19.5% in packages. This growth was largely driven by the rapid expansion of the company’s portfolio — in 2025, Ozon Pharmaceuticals offered 360 brands in retail. Binnopharm retained ninth place in the ranking; however, despite growth in value terms, its retail unit sales declined by 3.6%. Otcpharm closed the top ten, having lost two positions over the year. Its value growth amounted to 6.5%, while physical sales volumes decreased by 2.6%. This performance was largely due to the ongoing decline in Arbidol sales: compared with 2024, consumer spending on this product fell by 3%, while unit demand decreased by 20%. This trend has been observed for several consecutive years and is not specific to 2025.

TOP-10 corporations on the Russian retail pharmaceutical market in 2025 (value terms)